New treatment perspectives in autism spectrum disorders
Developing novel and more effective treatments that improve quality of life for individuals with autism spectrum disorders is urgently needed. To date a wide range of behavioral interventions have been shown to be safe and effective for improving language and cognition and adaptive behavior in child...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Online |
| Sprog: | engelsk |
| Udgivet: |
Frontiers Media SA
2021
|
| Fag: | |
| Online adgang: | 17826 |
| Tags: |
Ingen Tags, Vær først til at tagge denne postø!
|
| _version_ | 1869525555939901440 |
|---|---|
| author | Yuri Bozzi Roberto Canitano |
| author_browse | Roberto Canitano Yuri Bozzi |
| author_facet | Yuri Bozzi Roberto Canitano |
| author_sort | Yuri Bozzi |
| collection | Directory of Open Access Books |
| description | Developing novel and more effective treatments that improve quality of life for individuals with autism spectrum disorders is urgently needed. To date a wide range of behavioral interventions have been shown to be safe and effective for improving language and cognition and adaptive behavior in children and adolescents with ASD. However many people with ASD can receive additional benefit from targeted pharmacological interventions. One of the major drawback in setting up therapeutics intervention is the remarkable individual differences found across individuals with ASD. As a matter of fact the medications that are currently available address only symptoms associated with ASD and not the core domains of social and communication dysfunction. The pathogenesis paradigm shift of ASD towards synaptic abnormalities moved the research to pathway to disease that involve multiple systems and that are becoming the forefront of ASD treatment and are pointing toward the development of new targeted treatments. Some new therapeutics have been tested and others are being studied. In this context single gene disorders frequently associated with ASD such as Rett Syndrome, Fragile X and Tuberous Sclerosis have been of significant aid as neurobiology of these disorders is more clear and has a potential to shed light on the altered signaling in ASD. However much research is needed to further understand the basic mechanisms of disease and the relationship to idiopathic ASD. Clinical trials in children are underway with agents directed to core symptoms and to the associated disorders in the search of new therapeutics and progress are expected with possible new option for therapeutics in ASD in the upcoming future. Children and Adolescents with ASD and their families can provide important information about their experience with new treatments and this should be a priority for future research. In addition, research performed on genetic mouse models of ASD will keep on providing useful information on the molecular pathways disrupted in the disease, thus contributing to identify novel drug targets. |
| format | Online |
| id | doab-20.500.12854ir-54621 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Frontiers Media SA |
| publisherStr | Frontiers Media SA |
| record_format | ojs |
| spelling | doab-20.500.12854ir-546212024-03-31T13:08:55Z New treatment perspectives in autism spectrum disorders Yuri Bozzi Roberto Canitano R5-920 RJ1-570 Clinical Trial mouse model neurodevelopmental disorder Genetics autism thema EDItEUR::M Medicine and Nursing Developing novel and more effective treatments that improve quality of life for individuals with autism spectrum disorders is urgently needed. To date a wide range of behavioral interventions have been shown to be safe and effective for improving language and cognition and adaptive behavior in children and adolescents with ASD. However many people with ASD can receive additional benefit from targeted pharmacological interventions. One of the major drawback in setting up therapeutics intervention is the remarkable individual differences found across individuals with ASD. As a matter of fact the medications that are currently available address only symptoms associated with ASD and not the core domains of social and communication dysfunction. The pathogenesis paradigm shift of ASD towards synaptic abnormalities moved the research to pathway to disease that involve multiple systems and that are becoming the forefront of ASD treatment and are pointing toward the development of new targeted treatments. Some new therapeutics have been tested and others are being studied. In this context single gene disorders frequently associated with ASD such as Rett Syndrome, Fragile X and Tuberous Sclerosis have been of significant aid as neurobiology of these disorders is more clear and has a potential to shed light on the altered signaling in ASD. However much research is needed to further understand the basic mechanisms of disease and the relationship to idiopathic ASD. Clinical trials in children are underway with agents directed to core symptoms and to the associated disorders in the search of new therapeutics and progress are expected with possible new option for therapeutics in ASD in the upcoming future. Children and Adolescents with ASD and their families can provide important information about their experience with new treatments and this should be a priority for future research. In addition, research performed on genetic mouse models of ASD will keep on providing useful information on the molecular pathways disrupted in the disease, thus contributing to identify novel drug targets. 2021-02-11T20:57:07Z 2021-02-11T20:57:07Z 2015-12-10 11:59:06 2015 book 17826 16648714 9782889195305 https://directory.doabooks.org/handle/20.500.12854/54621 eng Frontiers Research Topics image/jpeg Attribution 4.0 International http://www.frontiersin.org/books/New_treatment_perspectives_in_autism_spectrum_disorders/498 http://journal.frontiersin.org/researchtopic/2032/new-treatment-perspectives-in-autism-spectrum-disorders Frontiers Media SA 10.3389/978-2-88919-530-5 10.3389/978-2-88919-530-5 bf5ce210-e72e-4860-ba9b-c305640ff3ae 9782889195305 161 open access |
| spellingShingle | R5-920 RJ1-570 Clinical Trial mouse model neurodevelopmental disorder Genetics autism thema EDItEUR::M Medicine and Nursing Yuri Bozzi Roberto Canitano New treatment perspectives in autism spectrum disorders |
| title | New treatment perspectives in autism spectrum disorders |
| title_full | New treatment perspectives in autism spectrum disorders |
| title_fullStr | New treatment perspectives in autism spectrum disorders |
| title_full_unstemmed | New treatment perspectives in autism spectrum disorders |
| title_short | New treatment perspectives in autism spectrum disorders |
| title_sort | new treatment perspectives in autism spectrum disorders |
| topic | R5-920 RJ1-570 Clinical Trial mouse model neurodevelopmental disorder Genetics autism thema EDItEUR::M Medicine and Nursing |
| topic_facet | R5-920 RJ1-570 Clinical Trial mouse model neurodevelopmental disorder Genetics autism thema EDItEUR::M Medicine and Nursing |
| url | 17826 |
| work_keys_str_mv | AT yuribozzi newtreatmentperspectivesinautismspectrumdisorders AT robertocanitano newtreatmentperspectivesinautismspectrumdisorders |